4.6 Review

Nrf2 is a potential therapeutic target in radioresistance in human cancer

Journal

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 88, Issue 3, Pages 706-715

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2013.09.001

Keywords

Nrf2; Radioresistance; ROS; Antioxidant; Targeted therapy

Funding

  1. Chinese National Natural Science Foundation [NSFC 81301922, 81302055]

Ask authors/readers for more resources

Radiation therapy can effectively kill cancer cells through ROS generation. Cancer cells with upregulated antioxidant systems can develop high radioresistance ability, and the transcription factor NF-E2-related factor 2 (Nrf2) is a key regulator of the antioxidant system. Currently, there are numerous data indicating the important role of Nrf2 in cancer radioresistance. In this review, we summarize the aberrant regulation of Nrf2 in radioresistant cells and discuss the effects and underlying mechanism of Nrf2 in promoting radioresistance. These findings suggest that Nrf2 might be a potential therapeutic target in cancer radiation resistance or a promising radioprotector for normal organs during radiation therapy in the future. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available